Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer’s disease mouse model
Clinical trials with rosiglitazone, a potent agonist at peroxisome proliferator-activated receptor gamma (PPARγ) suggest an improvement of cognitive function in Alzheimer’s disease (AD) patients. The mechanisms mediating this potential beneficial effect remain to be fully elucidated. In mice overexp...
Gespeichert in:
| Veröffentlicht in: | Biochemical and biophysical research communications 2009-02, Vol.379 (2), p.406-410 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 410 |
|---|---|
| container_issue | 2 |
| container_start_page | 406 |
| container_title | Biochemical and biophysical research communications |
| container_volume | 379 |
| creator | Escribano, Luis Simón, Ana-María Pérez-Mediavilla, Alberto Salazar-Colocho, Pablo Río, Joaquín Del Frechilla, Diana |
| description | Clinical trials with rosiglitazone, a potent agonist at peroxisome proliferator-activated receptor gamma (PPARγ) suggest an improvement of cognitive function in Alzheimer’s disease (AD) patients. The mechanisms mediating this potential beneficial effect remain to be fully elucidated. In mice overexpressing mutant human amyloid precursor protein (hAPP), a model of AD, we found that memory impairment in the object recognition test was prevented and also reversed by chronic rosiglitazone treatment. Given the possible involvement of glucocorticoid receptors (GR) in the actions of PPARγ-ligands, we studied the effect of chronic rosiglitazone treatment on GR levels in the hippocampus of hAPP mice. An early down-regulation of GR, not related to elevated plasma corticosterone levels, was found in different hippocampal subfields of the transgenic mice and this decrease was prevented by rosiglitazone. In parallel with behavioural studies, rosiglitazone also normalized GR levels in older animals. This effect may contribute to explain the attenuation of memory decline by PPARγ activation in an AD mouse model. |
| doi_str_mv | 10.1016/j.bbrc.2008.12.071 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_21255865</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006291X08024807</els_id><sourcerecordid>66838218</sourcerecordid><originalsourceid>FETCH-LOGICAL-c413t-fde95b478ff86e8501ebdf19416e5ed0f353a5b3b6228cce229d0991a46360bd3</originalsourceid><addsrcrecordid>eNqFkcGK1TAUhoMoznX0BVxIQHDXmpM2uS24GQYdhQFBFNyFNDm9N5e0qUk7MrNy40PM6_kkpt4L7nSTA-H7f85_fkKeAyuBgXx9KLsumpIz1pTAS7aFB2QDrGUFB1Y_JBvGmCx4C1_PyJOUDowB1LJ9TM6gzVjLtxvy81NIbufdrO_CiDTiDcaEiQ44hHhLLRrv8r8eLd27aQpGD5P2dOcXE0yIszPB2SwzOM0hUhu-j0XE3eL17MJI3Zil9MLf7dENGH_9uE_UuoQ6IR3C8ue16J-SR732CZ-d5jn58u7t58v3xfXHqw-XF9eFqaGai95iK7p62_R9I7ERDLCzPbQ1SBRoWV-JSouu6iTnjTHIeWtzTtC1rCTrbHVOXh59Q5qdSsbNaPYmjCOaWXHgQjRSZOrVkZpi-LZgmtXgkkHv9Yh5ZyVlUzUcmv-CnHFRCWgzyI-giSGliL2aoht0vFXA1NqlOqi1S7V2qYCr3GUWvTi5L92A9q_kVF4G3hwBzCe7cRjXRDgatC6ugWxw__L_DSdRs8Y</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20253519</pqid></control><display><type>article</type><title>Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer’s disease mouse model</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Escribano, Luis ; Simón, Ana-María ; Pérez-Mediavilla, Alberto ; Salazar-Colocho, Pablo ; Río, Joaquín Del ; Frechilla, Diana</creator><creatorcontrib>Escribano, Luis ; Simón, Ana-María ; Pérez-Mediavilla, Alberto ; Salazar-Colocho, Pablo ; Río, Joaquín Del ; Frechilla, Diana</creatorcontrib><description>Clinical trials with rosiglitazone, a potent agonist at peroxisome proliferator-activated receptor gamma (PPARγ) suggest an improvement of cognitive function in Alzheimer’s disease (AD) patients. The mechanisms mediating this potential beneficial effect remain to be fully elucidated. In mice overexpressing mutant human amyloid precursor protein (hAPP), a model of AD, we found that memory impairment in the object recognition test was prevented and also reversed by chronic rosiglitazone treatment. Given the possible involvement of glucocorticoid receptors (GR) in the actions of PPARγ-ligands, we studied the effect of chronic rosiglitazone treatment on GR levels in the hippocampus of hAPP mice. An early down-regulation of GR, not related to elevated plasma corticosterone levels, was found in different hippocampal subfields of the transgenic mice and this decrease was prevented by rosiglitazone. In parallel with behavioural studies, rosiglitazone also normalized GR levels in older animals. This effect may contribute to explain the attenuation of memory decline by PPARγ activation in an AD mouse model.</description><identifier>ISSN: 0006-291X</identifier><identifier>EISSN: 1090-2104</identifier><identifier>DOI: 10.1016/j.bbrc.2008.12.071</identifier><identifier>PMID: 19109927</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>60 APPLIED LIFE SCIENCES ; Administration, Oral ; Alzheimer Disease - blood ; Alzheimer Disease - complications ; Alzheimer Disease - genetics ; Alzheimer’s disease ; Amyloid beta-Protein Precursor - genetics ; Amyloid beta-Protein Precursor - metabolism ; Animals ; BLOOD PLASMA ; CLINICAL TRIALS ; CORTICOSTERONE ; Down-Regulation ; GENE REGULATION ; Glucocorticoids ; HIPPOCAMPUS ; Hippocampus - drug effects ; Hippocampus - metabolism ; HUMAN POPULATIONS ; Humans ; Memory ; Memory Disorders - blood ; Memory Disorders - genetics ; Memory Disorders - prevention & control ; Mice ; Mice, Transgenic ; MUTANTS ; NERVOUS SYSTEM DISEASES ; Peroxisome proliferator-activated receptor-γ ; PPAR gamma - agonists ; PPAR gamma - metabolism ; RECEPTORS ; Receptors, Glucocorticoid - blood ; Receptors, Glucocorticoid - metabolism ; Thiazolidinediones - administration & dosage ; Thiazolidinediones - therapeutic use ; TRANSGENIC MICE</subject><ispartof>Biochemical and biophysical research communications, 2009-02, Vol.379 (2), p.406-410</ispartof><rights>2008 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c413t-fde95b478ff86e8501ebdf19416e5ed0f353a5b3b6228cce229d0991a46360bd3</citedby><cites>FETCH-LOGICAL-c413t-fde95b478ff86e8501ebdf19416e5ed0f353a5b3b6228cce229d0991a46360bd3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0006291X08024807$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19109927$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/21255865$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Escribano, Luis</creatorcontrib><creatorcontrib>Simón, Ana-María</creatorcontrib><creatorcontrib>Pérez-Mediavilla, Alberto</creatorcontrib><creatorcontrib>Salazar-Colocho, Pablo</creatorcontrib><creatorcontrib>Río, Joaquín Del</creatorcontrib><creatorcontrib>Frechilla, Diana</creatorcontrib><title>Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer’s disease mouse model</title><title>Biochemical and biophysical research communications</title><addtitle>Biochem Biophys Res Commun</addtitle><description>Clinical trials with rosiglitazone, a potent agonist at peroxisome proliferator-activated receptor gamma (PPARγ) suggest an improvement of cognitive function in Alzheimer’s disease (AD) patients. The mechanisms mediating this potential beneficial effect remain to be fully elucidated. In mice overexpressing mutant human amyloid precursor protein (hAPP), a model of AD, we found that memory impairment in the object recognition test was prevented and also reversed by chronic rosiglitazone treatment. Given the possible involvement of glucocorticoid receptors (GR) in the actions of PPARγ-ligands, we studied the effect of chronic rosiglitazone treatment on GR levels in the hippocampus of hAPP mice. An early down-regulation of GR, not related to elevated plasma corticosterone levels, was found in different hippocampal subfields of the transgenic mice and this decrease was prevented by rosiglitazone. In parallel with behavioural studies, rosiglitazone also normalized GR levels in older animals. This effect may contribute to explain the attenuation of memory decline by PPARγ activation in an AD mouse model.</description><subject>60 APPLIED LIFE SCIENCES</subject><subject>Administration, Oral</subject><subject>Alzheimer Disease - blood</subject><subject>Alzheimer Disease - complications</subject><subject>Alzheimer Disease - genetics</subject><subject>Alzheimer’s disease</subject><subject>Amyloid beta-Protein Precursor - genetics</subject><subject>Amyloid beta-Protein Precursor - metabolism</subject><subject>Animals</subject><subject>BLOOD PLASMA</subject><subject>CLINICAL TRIALS</subject><subject>CORTICOSTERONE</subject><subject>Down-Regulation</subject><subject>GENE REGULATION</subject><subject>Glucocorticoids</subject><subject>HIPPOCAMPUS</subject><subject>Hippocampus - drug effects</subject><subject>Hippocampus - metabolism</subject><subject>HUMAN POPULATIONS</subject><subject>Humans</subject><subject>Memory</subject><subject>Memory Disorders - blood</subject><subject>Memory Disorders - genetics</subject><subject>Memory Disorders - prevention & control</subject><subject>Mice</subject><subject>Mice, Transgenic</subject><subject>MUTANTS</subject><subject>NERVOUS SYSTEM DISEASES</subject><subject>Peroxisome proliferator-activated receptor-γ</subject><subject>PPAR gamma - agonists</subject><subject>PPAR gamma - metabolism</subject><subject>RECEPTORS</subject><subject>Receptors, Glucocorticoid - blood</subject><subject>Receptors, Glucocorticoid - metabolism</subject><subject>Thiazolidinediones - administration & dosage</subject><subject>Thiazolidinediones - therapeutic use</subject><subject>TRANSGENIC MICE</subject><issn>0006-291X</issn><issn>1090-2104</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcGK1TAUhoMoznX0BVxIQHDXmpM2uS24GQYdhQFBFNyFNDm9N5e0qUk7MrNy40PM6_kkpt4L7nSTA-H7f85_fkKeAyuBgXx9KLsumpIz1pTAS7aFB2QDrGUFB1Y_JBvGmCx4C1_PyJOUDowB1LJ9TM6gzVjLtxvy81NIbufdrO_CiDTiDcaEiQ44hHhLLRrv8r8eLd27aQpGD5P2dOcXE0yIszPB2SwzOM0hUhu-j0XE3eL17MJI3Zil9MLf7dENGH_9uE_UuoQ6IR3C8ue16J-SR732CZ-d5jn58u7t58v3xfXHqw-XF9eFqaGai95iK7p62_R9I7ERDLCzPbQ1SBRoWV-JSouu6iTnjTHIeWtzTtC1rCTrbHVOXh59Q5qdSsbNaPYmjCOaWXHgQjRSZOrVkZpi-LZgmtXgkkHv9Yh5ZyVlUzUcmv-CnHFRCWgzyI-giSGliL2aoht0vFXA1NqlOqi1S7V2qYCr3GUWvTi5L92A9q_kVF4G3hwBzCe7cRjXRDgatC6ugWxw__L_DSdRs8Y</recordid><startdate>20090206</startdate><enddate>20090206</enddate><creator>Escribano, Luis</creator><creator>Simón, Ana-María</creator><creator>Pérez-Mediavilla, Alberto</creator><creator>Salazar-Colocho, Pablo</creator><creator>Río, Joaquín Del</creator><creator>Frechilla, Diana</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>OTOTI</scope></search><sort><creationdate>20090206</creationdate><title>Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer’s disease mouse model</title><author>Escribano, Luis ; Simón, Ana-María ; Pérez-Mediavilla, Alberto ; Salazar-Colocho, Pablo ; Río, Joaquín Del ; Frechilla, Diana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c413t-fde95b478ff86e8501ebdf19416e5ed0f353a5b3b6228cce229d0991a46360bd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>60 APPLIED LIFE SCIENCES</topic><topic>Administration, Oral</topic><topic>Alzheimer Disease - blood</topic><topic>Alzheimer Disease - complications</topic><topic>Alzheimer Disease - genetics</topic><topic>Alzheimer’s disease</topic><topic>Amyloid beta-Protein Precursor - genetics</topic><topic>Amyloid beta-Protein Precursor - metabolism</topic><topic>Animals</topic><topic>BLOOD PLASMA</topic><topic>CLINICAL TRIALS</topic><topic>CORTICOSTERONE</topic><topic>Down-Regulation</topic><topic>GENE REGULATION</topic><topic>Glucocorticoids</topic><topic>HIPPOCAMPUS</topic><topic>Hippocampus - drug effects</topic><topic>Hippocampus - metabolism</topic><topic>HUMAN POPULATIONS</topic><topic>Humans</topic><topic>Memory</topic><topic>Memory Disorders - blood</topic><topic>Memory Disorders - genetics</topic><topic>Memory Disorders - prevention & control</topic><topic>Mice</topic><topic>Mice, Transgenic</topic><topic>MUTANTS</topic><topic>NERVOUS SYSTEM DISEASES</topic><topic>Peroxisome proliferator-activated receptor-γ</topic><topic>PPAR gamma - agonists</topic><topic>PPAR gamma - metabolism</topic><topic>RECEPTORS</topic><topic>Receptors, Glucocorticoid - blood</topic><topic>Receptors, Glucocorticoid - metabolism</topic><topic>Thiazolidinediones - administration & dosage</topic><topic>Thiazolidinediones - therapeutic use</topic><topic>TRANSGENIC MICE</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Escribano, Luis</creatorcontrib><creatorcontrib>Simón, Ana-María</creatorcontrib><creatorcontrib>Pérez-Mediavilla, Alberto</creatorcontrib><creatorcontrib>Salazar-Colocho, Pablo</creatorcontrib><creatorcontrib>Río, Joaquín Del</creatorcontrib><creatorcontrib>Frechilla, Diana</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>OSTI.GOV</collection><jtitle>Biochemical and biophysical research communications</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Escribano, Luis</au><au>Simón, Ana-María</au><au>Pérez-Mediavilla, Alberto</au><au>Salazar-Colocho, Pablo</au><au>Río, Joaquín Del</au><au>Frechilla, Diana</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer’s disease mouse model</atitle><jtitle>Biochemical and biophysical research communications</jtitle><addtitle>Biochem Biophys Res Commun</addtitle><date>2009-02-06</date><risdate>2009</risdate><volume>379</volume><issue>2</issue><spage>406</spage><epage>410</epage><pages>406-410</pages><issn>0006-291X</issn><eissn>1090-2104</eissn><abstract>Clinical trials with rosiglitazone, a potent agonist at peroxisome proliferator-activated receptor gamma (PPARγ) suggest an improvement of cognitive function in Alzheimer’s disease (AD) patients. The mechanisms mediating this potential beneficial effect remain to be fully elucidated. In mice overexpressing mutant human amyloid precursor protein (hAPP), a model of AD, we found that memory impairment in the object recognition test was prevented and also reversed by chronic rosiglitazone treatment. Given the possible involvement of glucocorticoid receptors (GR) in the actions of PPARγ-ligands, we studied the effect of chronic rosiglitazone treatment on GR levels in the hippocampus of hAPP mice. An early down-regulation of GR, not related to elevated plasma corticosterone levels, was found in different hippocampal subfields of the transgenic mice and this decrease was prevented by rosiglitazone. In parallel with behavioural studies, rosiglitazone also normalized GR levels in older animals. This effect may contribute to explain the attenuation of memory decline by PPARγ activation in an AD mouse model.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>19109927</pmid><doi>10.1016/j.bbrc.2008.12.071</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0006-291X |
| ispartof | Biochemical and biophysical research communications, 2009-02, Vol.379 (2), p.406-410 |
| issn | 0006-291X 1090-2104 |
| language | eng |
| recordid | cdi_osti_scitechconnect_21255865 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | 60 APPLIED LIFE SCIENCES Administration, Oral Alzheimer Disease - blood Alzheimer Disease - complications Alzheimer Disease - genetics Alzheimer’s disease Amyloid beta-Protein Precursor - genetics Amyloid beta-Protein Precursor - metabolism Animals BLOOD PLASMA CLINICAL TRIALS CORTICOSTERONE Down-Regulation GENE REGULATION Glucocorticoids HIPPOCAMPUS Hippocampus - drug effects Hippocampus - metabolism HUMAN POPULATIONS Humans Memory Memory Disorders - blood Memory Disorders - genetics Memory Disorders - prevention & control Mice Mice, Transgenic MUTANTS NERVOUS SYSTEM DISEASES Peroxisome proliferator-activated receptor-γ PPAR gamma - agonists PPAR gamma - metabolism RECEPTORS Receptors, Glucocorticoid - blood Receptors, Glucocorticoid - metabolism Thiazolidinediones - administration & dosage Thiazolidinediones - therapeutic use TRANSGENIC MICE |
| title | Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer’s disease mouse model |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T00%3A20%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Rosiglitazone%20reverses%20memory%20decline%20and%20hippocampal%20glucocorticoid%20receptor%20down-regulation%20in%20an%20Alzheimer%E2%80%99s%20disease%20mouse%20model&rft.jtitle=Biochemical%20and%20biophysical%20research%20communications&rft.au=Escribano,%20Luis&rft.date=2009-02-06&rft.volume=379&rft.issue=2&rft.spage=406&rft.epage=410&rft.pages=406-410&rft.issn=0006-291X&rft.eissn=1090-2104&rft_id=info:doi/10.1016/j.bbrc.2008.12.071&rft_dat=%3Cproquest_osti_%3E66838218%3C/proquest_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20253519&rft_id=info:pmid/19109927&rft_els_id=S0006291X08024807&rfr_iscdi=true |